These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 18184959

  • 1. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN.
    N Engl J Med; 2008 Jan 10; 358(2):140-51. PubMed ID: 18184959
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
    Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR.
    N Engl J Med; 2008 Jan 10; 358(2):200-3. PubMed ID: 18184971
    [No Abstract] [Full Text] [Related]

  • 3. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
    Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR.
    Clin Cancer Res; 2011 Jun 15; 17(12):4071-81. PubMed ID: 21525172
    [Abstract] [Full Text] [Related]

  • 4. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y, Guo H, Wang W, Li H, Sun H, Shi B, Zhang Y.
    Orphanet J Rare Dis; 2018 Mar 27; 13(1):43. PubMed ID: 29587809
    [Abstract] [Full Text] [Related]

  • 5. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
    Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K.
    Lancet; 2013 Mar 09; 381(9869):817-24. PubMed ID: 23312829
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
    Peng ZF, Yang L, Wang TT, Han P, Liu ZH, Wei Q.
    J Urol; 2014 Nov 09; 192(5):1424-30. PubMed ID: 24813310
    [Abstract] [Full Text] [Related]

  • 9. Lymphangioleiomyomatosis.
    Johnson SR, Taveira-DaSilva AM, Moss J.
    Clin Chest Med; 2016 Sep 09; 37(3):389-403. PubMed ID: 27514586
    [Abstract] [Full Text] [Related]

  • 10. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Berkowitz N, Miao S, Segal S, Peyrard S, Budde K.
    Nephrol Dial Transplant; 2016 Jan 09; 31(1):111-9. PubMed ID: 26156073
    [Abstract] [Full Text] [Related]

  • 11. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W, Guo H, Shi B, Sun H, Li H, Zhang Y, Cai Y.
    Int Urol Nephrol; 2019 Apr 09; 51(4):671-676. PubMed ID: 30756282
    [Abstract] [Full Text] [Related]

  • 12. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
    Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, Voi M, Peyrard S, Budde K.
    PLoS One; 2017 Apr 09; 12(8):e0180939. PubMed ID: 28792952
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.
    Franz DN, Krueger DA.
    Am J Med Genet C Semin Med Genet; 2018 Sep 09; 178(3):365-373. PubMed ID: 30307123
    [Abstract] [Full Text] [Related]

  • 17. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J, Parkhitko AA, Henske EP.
    Proc Am Thorac Soc; 2010 Feb 09; 7(1):48-53. PubMed ID: 20160148
    [Abstract] [Full Text] [Related]

  • 18. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
    Bissler JJ, Nonomura N, Budde K, Zonnenberg BA, Fischereder M, Voi M, Louveau AL, Herbst F, Bebin EM, Curatolo P, Zonta A, Belousova E.
    PLoS One; 2018 Feb 09; 13(9):e0201005. PubMed ID: 30192751
    [Abstract] [Full Text] [Related]

  • 19. Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy.
    Cleary-Goldman J, Sanghvi AV, Nakhuda GS, Robinson JN.
    J Matern Fetal Neonatal Med; 2004 Feb 09; 15(2):132-4. PubMed ID: 15209123
    [Abstract] [Full Text] [Related]

  • 20. Coexisting lymphangioleiomyomatosis and bilateral angiomyolipomas in a patient with tuberous sclerosis.
    Uzzo RG, Libby DM, Vaughan ED, Levey SH.
    J Urol; 1994 Jun 09; 151(6):1612-5. PubMed ID: 8189576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.